PROTAC

Cat.No. ์ œํ’ˆ๋ช… ์ •๋ณด
S0070 Gefitinib-based PROTAC 3 EGFR ๊ฒฐํ•ฉ ์š”์†Œ์™€ VHL ๋ฆฌ๊ฐ„๋“œ๋ฅผ ๋ง์ปค๋ฅผ ํ†ตํ•ด ๊ฒฐํ•ฉ์‹œํ‚จ Gefitinib-based PROTAC 3๋Š” HCC827(Exon 19 del) ๋ฐ H3255(L858R) ์„ธํฌ์—์„œ ๊ฐ๊ฐ 11.7 nM ๋ฐ 22.3 nM์˜ DC50์œผ๋กœ EGFR ๋ฐ ๋Œ์—ฐ๋ณ€์ด์˜ ๋ถ„ํ•ด๋ฅผ ์œ ๋„ํ•ฉ๋‹ˆ๋‹ค.
S0072 MS4078 MS4078์€ ALK์˜ ์–ต์ œ์ œ์ด์ž PROTAC(๋ถ„ํ•ด์ œ)์ž…๋‹ˆ๋‹ค. ์ด ํ™”ํ•ฉ๋ฌผ์€ SU-DHL-1 ์„ธํฌ์˜ NPM-ALK ๋‹จ๋ฐฑ์งˆ ์ˆ˜์น˜์™€ NCI-H2228 ์„ธํฌ์˜ EML4-ALK ๋‹จ๋ฐฑ์งˆ ์ˆ˜์น˜๋ฅผ ๊ฐ๊ฐ 11 nM ๋ฐ 59 nM์˜ DC50์œผ๋กœ ๊ฐ์†Œ์‹œํ‚ต๋‹ˆ๋‹ค. ์ด๋Š” cereblon ๋ฐ ํ”„๋กœํ…Œ์•„์ข€ ์˜์กด์  ๋ฉ”์ปค๋‹ˆ์ฆ˜์„ ํ†ตํ•ด ALK ๋‹จ๋ฐฑ์งˆ ๋ถ„ํ•ด๋ฅผ ์œ ๋„ํ•˜๋ฉฐ, 33 nM์˜ IC50์œผ๋กœ SU-DHL-1 ์„ธํฌ์˜ ์ฆ์‹์„ ๊ฐ•๋ ฅํ•˜๊ฒŒ ์–ต์ œํ•ฉ๋‹ˆ๋‹ค.
S0137 dBET57 dBET57์€ PROTAC ๊ธฐ์ˆ ์„ ๊ธฐ๋ฐ˜์œผ๋กœ ํ•˜๋Š” BRD4BD1์˜ ์ƒˆ๋กญ๊ณ  ๊ฐ•๋ ฅํ•˜๋ฉฐ ์„ ํƒ์ ์ธ ๋ถ„ํ•ด์ œ๋กœ, DC50/5h๋Š” 500 nM์ž…๋‹ˆ๋‹ค. ์ด ํ™”ํ•ฉ๋ฌผ์€ BRD4BD2์— ๋Œ€ํ•ด์„œ๋Š” ๋น„ํ™œ์„ฑ์ž…๋‹ˆ๋‹ค.
S8296 dBET1 dBET1์€ IC50์ด 20 nM์ธ CRBN ๊ธฐ๋ฐ˜ BET ๋ถ„ํ•ด์ œ๋กœ, ๋งค์šฐ ๋†’์€ ์„ ํƒ์„ฑ์„ ๋‚˜ํƒ€๋ƒ…๋‹ˆ๋‹ค. 7,429๊ฐœ์˜ ๋‹จ๋ฐฑ์งˆ ์ค‘ ์ด ํ™”ํ•ฉ๋ฌผ ์ฒ˜๋ฆฌ์— ์˜ํ•ด ์ข…์–‘ ๋‹จ๋ฐฑ์งˆ์ธ MYC์™€ PIM1, ๊ทธ๋ฆฌ๊ณ  BRD2, BRD3, BRD4์˜ ๋ฐœํ˜„๋งŒ์ด ์œ ์˜๋ฏธํ•˜๊ฒŒ ํ•˜ํ–ฅ ์กฐ์ ˆ๋˜์—ˆ์Šต๋‹ˆ๋‹ค.
S8297 ARV-825 ARV-825๋Š” E3 ์œ ๋น„ํ€ดํ‹ด ๋ฆฌ๊ฐ€์•„์ œ cereblon์— BRD4๋ฅผ ๋ชจ์ง‘ํ•˜์—ฌ BRD4์˜ ๋น ๋ฅด๊ณ  ํšจ์œจ์ ์ด๋ฉฐ ์žฅ๊ธฐ์ ์ธ ๋ถ„ํ•ด์™€ MYC์˜ ์ง€์†์ ์ธ ํ•˜ํ–ฅ ์กฐ์ ˆ์„ ์œ ๋„ํ•˜๋Š” BRD4 ์–ต์ œ์ œ์ธ PROTAC์ž…๋‹ˆ๋‹ค.
S8532 ARV-771 ARV-771์€ ๊ฐ•๋ ฅํ•œ pan-(bromodomain and extra-terminal)BET ๋ถ„ํ•ด์ œ์ด๋ฉฐ, BRD2(1), BRD2(2), BRD3(1), BRD3(2), BRD4(1) ๋ฐ BRD4(2)์— ๋Œ€ํ•ด ๊ฐ๊ฐ 34 nM, 4.7 nM, 8.3 nM, 7.6 nM, 9.6 nM ๋ฐ 7.6 nM์˜ Kd ๊ฐ’์„ ๊ฐ€์ง€๋Š” ์ƒˆ๋กœ์šด BET-PROTAC(๋‹จ๋ฐฑ์งˆ ๋ถ„ํ•ด ํ‘œ์  ํ‚ค๋ฉ”๋ผ)์ž…๋‹ˆ๋‹ค.
S8762 dBET6 dBET6๋Š” BET bromodomains์— ๋Œ€ํ•ด 14 nM์˜ IC50์œผ๋กœ ๊ฒฐํ•ฉํ•˜๋Š” ์„ธํฌ ํˆฌ๊ณผ์„ฑ์ด ๋งค์šฐ ๋†’์€ PROTAC degrader์ž…๋‹ˆ๋‹ค. ๋˜ํ•œ dBET6๋Š” c-MYC ํ•˜ํ–ฅ ์กฐ์ ˆ ๋ฐ Apoptosis related๋ฅผ ์œ ๋„ํ•ฉ๋‹ˆ๋‹ค.
S8785 A1874 A1874๋Š” ํ›จ์”ฌ ๊ฐœ์„ ๋œ nutlin ๊ธฐ๋ฐ˜์˜ BRD4-degrading PROTAC์œผ๋กœ, ๋‚˜๋…ธ๋ชฐ(nanomolar) ๋†๋„์—์„œ ํ‘œ์  ๋‹จ๋ฐฑ์งˆ์„ 98%๊นŒ์ง€ ๋ถ„ํ•ดํ•  ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.
S8888 GMB-475 GMB-475๋Š” BCR-ABL1 ๋‹จ๋ฐฑ์งˆ์„ ์•Œ๋กœ์Šคํ…Œ๋ฆญํ•˜๊ฒŒ ํ‘œ์ ํ•˜๊ณ  E3 Ligase์ธ VHL(Von Hippel-Lindau)์„ ๋ชจ์ง‘ํ•˜์—ฌ ์ข…์–‘ ์œ ๋ฐœ ์œตํ•ฉ ๋‹จ๋ฐฑ์งˆ์˜ ์œ ๋น„ํ€ดํ‹ดํ™” ๋ฐ ํ›„์† ๋ถ„ํ•ด๋ฅผ ์œ ๋„ํ•˜๋Š” PROTAC(proteolysis-targeting chimera)์ž…๋‹ˆ๋‹ค.
S0603 m-PEG12-amine m-PEG12-amine์€ PROTAC ํ•ฉ์„ฑ์— ์ ์šฉํ•  ์ˆ˜ ์žˆ๋Š” PEG ๊ธฐ๋ฐ˜ PROTAC Linker์ž…๋‹ˆ๋‹ค. ์ด ํ™”ํ•ฉ๋ฌผ์€ ๋˜ํ•œ ํ•ญ์ฒด-์•ฝ๋ฌผ ์ ‘ํ•ฉ์ฒด(ADC) ํ•ฉ์„ฑ์— ์ ์šฉ๋˜๋Š” ์ ˆ๋‹จ ๋ถˆ๊ฐ€๋Šฅํ•œ 12๋‹จ์œ„ PEG ADC Linker์ด๊ธฐ๋„ ํ•ฉ๋‹ˆ๋‹ค.
S1127 3-Maleimidopropionic acid 3-Maleimidopropionic acid๋Š” PROTAC ํ•ฉ์„ฑ์— ์ ์šฉํ•  ์ˆ˜ ์žˆ๋Š” ์•Œํ‚ฌ ์‚ฌ์Šฌ ๊ธฐ๋ฐ˜ PROTAC linker์ž…๋‹ˆ๋‹ค. Others
S1246 NH2-PEG3-C2-NH-Boc NH2-PEG3-C2-Boc (PROTAC Linker 15)์€ PROTAC ํ•ฉ์„ฑ์— ์‚ฌ์šฉํ•  ์ˆ˜ ์žˆ๋Š” PEG ๊ธฐ๋ฐ˜ PROTAC Linker์ž…๋‹ˆ๋‹ค.
S1350 Bis-PEG3-acid Bis-PEG3-acid๋Š” PROTAC ํ•ฉ์„ฑ ๋‹จ๊ณ„์—์„œ ์‚ฌ์šฉ๋  ์ˆ˜ ์žˆ๋Š” PEG ๊ธฐ๋ฐ˜์˜ PROTAC Linker์ž…๋‹ˆ๋‹ค.
S1661 5-Ethynyl-2'-deoxyuridine (EdU) 5-Ethynyl-2'-deoxyuridine (EdU)๋Š” ํ‹ฐ๋ฏธ๋”˜ ์œ ์‚ฌ์ฒด๋กœ์„œ ์„ธํฌ DNA์— ํ†ตํ•ฉ๋  ์ˆ˜ ์žˆ์œผ๋ฉฐ, ์ดํ›„ ๊ตฌ๋ฆฌ ์ด‰๋งค [3+2] ๊ณ ๋ฆฌํ™” ์ฒจ๊ฐ€ ๋ฐ˜์‘("Click" ๋ฐ˜์‘)์„ ํ†ตํ•ด ํ˜•๊ด‘ ์•„์ž์ด๋“œ์™€ EdU๊ฐ€ ๋ฐ˜์‘ํ•˜์—ฌ DNA ํ•ฉ์„ฑ์„ ๊ฒ€์ถœํ•˜๋Š” ๋ฐฉ๋ฒ•์œผ๋กœ ๊ฐœ๋ฐœ๋˜์—ˆ์Šต๋‹ˆ๋‹ค. 5-Ethynyl-2'-deoxyuridine์€ PROTACs ํ•ฉ์„ฑ์— ์ ์šฉ ๊ฐ€๋Šฅํ•œ ์•Œํ‚ฌ ์‚ฌ์Šฌ ๊ธฐ๋ฐ˜์˜ PROTAC Linker์ž…๋‹ˆ๋‹ค.
S1664 Di(N-succinimidyl) adipate Di(N-succinimidyl) adipate (DSAP)์€ PROTAC ํ•ฉ์„ฑ์˜ ์ ์šฉ ๊ฐ€๋Šฅํ•œ ์•Œํ‚ฌ ์‚ฌ์Šฌ ๊ธฐ๋ฐ˜ PROTAC Linker์ž…๋‹ˆ๋‹ค.
S1697 Heptaethylene glycol Heptaethylene glycol(HO-PEG7-OH)์€ PROTAC ํ•ฉ์„ฑ์— ์ ์šฉํ•  ์ˆ˜ ์žˆ๋Š” PEG ๊ธฐ๋ฐ˜์˜ PROTAC Linker์ž…๋‹ˆ๋‹ค.
S1772 Bis-NH2-C1-PEG3 Bis-NH2-C1-PEG3 (PROTAC Linker 24)์€ PROTAC ํ•ฉ์„ฑ์— ์ ์šฉ ๊ฐ€๋Šฅํ•œ PEG ๊ธฐ๋ฐ˜ PROTAC Linker์ž…๋‹ˆ๋‹ค.
S1803 5-Boc-amino-pentanoic acid 5-Boc-amino-pentanoic acid (Boc-5-aminovaleric acid, Boc-NH-C4-acid, Boc-5-Ava-OH)์€ Alkyl/ether linker์— ์†ํ•˜๋Š” PROTAC Linker์ž…๋‹ˆ๋‹ค. Boc-NH-C4-acid๋Š” PROTAC1์˜ ํ•ฉ์„ฑ์— ์ ์šฉํ•  ์ˆ˜ ์žˆ์œผ๋ฉฐ, ํŠนํžˆ PRC2 Complex ๋‚ด์˜ EED, EZH2 ๋ฐ SUZ12๋ฅผ ๋ถ„ํ•ดํ•ฉ๋‹ˆ๋‹ค.
S1814 tert-Butyl 11-aminoundecanoate tert-Butyl 11-aminoundecanoate (compound 6b)๋Š” PEG ๊ตฌ์„ฑ์„ ์ง€์นญํ•˜๋Š” PROTAC Linker์ž…๋‹ˆ๋‹ค. ์ด ํ™”ํ•ฉ๋ฌผ์€ ์ผ๋ จ์˜ PROTACs ํ•ฉ์„ฑ์— ์ ์šฉํ•  ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.
S1846 Hydroxy-PEG4-O-Boc Hydroxy-PEG4-O-Boc์€ PROTAC ํ•ฉ์„ฑ์— ์‚ฌ์šฉํ•  ์ˆ˜ ์žˆ๋Š” PEG ๊ธฐ๋ฐ˜ PROTAC Linker์ž…๋‹ˆ๋‹ค.
S1872 Amino-PEG1-C2-acid Amino-PEG1-C2-acid๋Š” PROTAC ํ•ฉ์„ฑ์— ์‚ฌ์šฉํ•  ์ˆ˜ ์žˆ๋Š” PEG ๊ธฐ๋ฐ˜ PROTAC ๋ง์ปค์ž…๋‹ˆ๋‹ค.
S1912 3,6,9-Trioxaundecanedioic Acid 3,6,9-Trioxaundecanedioic Acid๋Š” PROTAC ํ•ฉ์„ฑ์— ์ ์šฉ ๊ฐ€๋Šฅํ•œ PEG ๊ธฐ๋ฐ˜ PROTAC Linker์ž…๋‹ˆ๋‹ค.
S0095 VL285 VL285๋Š” HaloTag7 ์œตํ•ฉ ๋‹จ๋ฐฑ์งˆ์„ ๋ถ„ํ•ดํ•˜๋Š” ๊ฐ•๋ ฅํ•œ VHL ligand์ž…๋‹ˆ๋‹ค. HaloPROTAC3์˜ ํ•ต์‹ฌ VHL ligand์ธ ์ด ํ™”ํ•ฉ๋ฌผ์„ ๊ณผ๋Ÿ‰์œผ๋กœ ๋ณ‘์šฉ ์ฒ˜๋ฆฌํ•˜๋ฉด HaloPROTAC3 ๋งค๊ฐœ ํ™œ์„ฑ์„ 50% ๋ถ„ํ•ด ์ˆ˜์ค€์œผ๋กœ ์œ ์˜ํ•˜๊ฒŒ ๊ฐ์†Œ์‹œํ‚ฌ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.
S0097 (S,R,S)-AHPC (MDK7526) (S,R,S)-AHPC (MDK7526, VH032-NH2, VHL ligand 1)์€ von Hippel-Lindau (VHL) ๋‹จ๋ฐฑ์งˆ์˜ ๋ชจ์ง‘์— ์‚ฌ์šฉ๋˜๋Š” VH032-based VHL ligand์ž…๋‹ˆ๋‹ค. (S,R,S)-AHPC๋Š” Androgen Receptor์˜ ํ‘œ์  ๋ถ„ํ•ด์— ์ž ์žฌ์ ์œผ๋กœ ์œ ์šฉํ•ฉ๋‹ˆ๋‹ค. (S,R,S)-AHPC๋Š” ๋ง์ปค๋ฅผ ํ†ตํ•ด BCR-ABL1๊ณผ ๊ฐ™์€ ๋‹จ๋ฐฑ์งˆ์šฉ ๋ฆฌ๊ฐ„๋“œ์— ์—ฐ๊ฒฐ๋˜์–ด GMB-475์™€ ๊ฐ™์€ PROTAC์„ ํ˜•์„ฑํ•  ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค. GMB-475๋Š” Ba/F3 ์„ธํฌ์—์„œ 1.11 ฮผM์˜ IC50์œผ๋กœ BCR-ABL1์˜ ๋ถ„ํ•ด๋ฅผ ์œ ๋„ํ•ฉ๋‹ˆ๋‹ค.
S0322 BC-1215 BC-1215๋Š” F-box protein 3 (Fbxo3, a ubiquitin E3 ligase component)์˜ ์–ต์ œ์ œ๋กœ, IL-1ฮฒ ๋ฐฉ์ถœ์— ๋Œ€ํ•œ IC50์€ 0.9 ฮผg/mL์ด๊ณ  LC50์€ 87 ฮผg/ml์ž…๋‹ˆ๋‹ค. ์ด ํ™”ํ•ฉ๋ฌผ์€ TRAF1-6์„ ๋ถˆ์•ˆ์ •ํ™”ํ•˜์—ฌ Fbxo3-TRAF ํ™œ์„ฑํ™” ๊ฒฝ๋กœ๋ฅผ ์–ต์ œํ•ฉ๋‹ˆ๋‹ค.
S1015 Thalidomide-OH Thalidomide-OH(Cereblon ligand 2, E3 ligase Ligand 2)์€ ์ถ”์ •๋˜๋Š” ํ•˜์ด๋“œ๋ก์‹คํ™” ํƒˆ๋ฆฌ๋„๋งˆ์ด๋“œ ๋Œ€์‚ฌ์‚ฐ๋ฌผ๋กœ, ์•ฝํ•œ ํ•ญํ˜ˆ๊ด€์‹ ์ƒ ํ™œ์„ฑ(100 ฮผg์—์„œ ํ˜ˆ๊ด€ ๋ฐ€๋„ ํ‰๊ท  ์–ต์ œ์œจ์€ 14%)์„ ๊ฐ€์ง€๋ฉฐ CRBN ๋‹จ๋ฐฑ์งˆ ๋ชจ์ง‘์—๋„ ์ ์šฉ๋  ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.
S1016 Lenalidomide-Br Lenalidomide-Br๋Š” PROTAC ์—ฐ๊ตฌ์—์„œ ํ™”ํ•™์  ๋„๊ตฌ๋กœ ์‚ฌ์šฉํ•˜๊ธฐ ์œ„ํ•ด ์„ค๊ณ„๋œ lenalidomide์˜ ๋ธŒ๋กฌํ™” ์œ ์‚ฌ์ฒด์ž…๋‹ˆ๋‹ค. ์ด ๋ฌผ์งˆ์€ cereblon (CRBN) ๋ชจ์ง‘ ๋ฆฌ๊ฐ„๋“œ ์—ญํ• ์„ ํ•˜๋ฉฐ, CRL4CRBN E3 ์œ ๋น„ํ€ดํ‹ด ๋ฆฌ๊ฐ€์•„์ œ ๋ณตํ•ฉ์ฒด๋ฅผ ํ†ตํ•ด ํ‘œ์  ๋‹จ๋ฐฑ์งˆ ๋ถ„ํ•ด๋ฅผ ๊ฐ€๋Šฅํ•˜๊ฒŒ ํ•ฉ๋‹ˆ๋‹ค.
S1029 CC-5013 (Lenalidomide) Lenalidomide๋Š” PBMC์—์„œ 13 nM์˜ IC50์„ ๊ฐ–๋Š” TNF-alpha ๋ถ„๋น„ ์–ต์ œ์ œ์ž…๋‹ˆ๋‹ค. Lenalidomide(CC-5013)๋Š” ubiquitin E3 ligase cereblon(CRBN)์˜ ๋ฆฌ๊ฐ„๋“œ์ด๋ฉฐ, CRBN-CRL4 ubiquitin ligase์— ์˜ํ•ด ๋‘ ๊ฐ€์ง€ ๋ฆผํ”„๊ตฌ ์ „์‚ฌ ์ธ์ž์ธ IKZF1 ๋ฐ IKZF3์˜ ์„ ํƒ์  ์œ ๋น„ํ€ดํ‹ดํ™” ๋ฐ ๋ถ„ํ•ด๋ฅผ ์œ ๋ฐœํ•ฉ๋‹ˆ๋‹ค. Lenalidomide๋Š” cleaved caspase-3 ๋ฐœํ˜„์„ ์ด‰์ง„ํ•˜๊ณ  VEGF ๋ฐœํ˜„์„ ์–ต์ œํ•˜๋ฉฐ apoptosis๋ฅผ ์œ ๋„ํ•ฉ๋‹ˆ๋‹ค.
S1062 (S,R,S)-AHPC hydrochloride (S,R,S)-AHPC hydrochloride (VH032-NH2, VHL ligand 1)์€ von Hippel-Lindau (VHL) ๋‹จ๋ฐฑ์งˆ์˜ ๋ชจ์ง‘์— ์ ์šฉ ๊ฐ€๋Šฅํ•œ VH032 ๊ธฐ๋ฐ˜ VHL ligand์ž…๋‹ˆ๋‹ค. ์ด ํ™”ํ•ฉ๋ฌผ์€ ๋ง์ปค๋ฅผ ํ†ตํ•ด ํ‘œ์  ๋‹จ๋ฐฑ์งˆ ๋ฆฌ๊ฐ„๋“œ์™€ ์—ฐ๊ฒฐ๋˜์–ด PROTAC์„ ํ˜•์„ฑํ•  ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.
S1193 Thalidomide Thalidomide๋Š” ์ง„์ •์ œ ๋ฐ ๋ฉด์—ญ ์กฐ์ ˆ์ œ๋กœ ๋„์ž…๋˜์—ˆ์œผ๋ฉฐ, ๋งŽ์€ ์•”์˜ ์ฆ์ƒ์„ ์น˜๋ฃŒํ•˜๊ธฐ ์œ„ํ•œ ์—ฐ๊ตฌ๊ฐ€ ์ง„ํ–‰๋˜๊ณ  ์žˆ์Šต๋‹ˆ๋‹ค. ์ด ํ™”ํ•ฉ๋ฌผ์€ cullin-4 E3 Ubiquitin ligase ๋ณตํ•ฉ์ฒด์ธ CUL4-RBX1-DDB1์˜ ์ผ๋ถ€์ธ cereblon(CRBN)์„ ์–ต์ œํ•ฉ๋‹ˆ๋‹ค.
S1567 Pomalidomide (CC-4047) Pomalidomide (CC-4047)๋Š” PBMCs์—์„œ 13 nM์˜ IC50์œผ๋กœ LPS ์œ ๋„ TNF-alpha ๋ฐฉ์ถœ์„ ์–ต์ œํ•ฉ๋‹ˆ๋‹ค. Pomalidomide (CC-4047)๋Š” E3 ligase Ligand๋กœ PROTAC์— ํ™œ์šฉ๋˜์–ด E3 ligase๋ฅผ ํ‘œ์ ์œผ๋กœ ์‚ผ๊ณ  E3 ligase protein cereblon (CRBN)์„ ์–ต์ œํ•  ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค. Pomalidomide (CC-4047)๋Š” Apoptosis related ๋ฐ ์„ธํฌ ์ฃผ๊ธฐ ์ •์ง€๋ฅผ ์ด‰์ง„ํ•ฉ๋‹ˆ๋‹ค.
S6794 Thalidomide-O-COOH (Cereblon ligand 3) Thalidomide-O-COOH (Cereblon ligand 3, E3 ligase Ligand 3)์€ CRBN ๋‹จ๋ฐฑ์งˆ ๋ชจ์ง‘์— ์‚ฌ์šฉ๋˜๋Š” Thalidomide ๊ธฐ๋ฐ˜ Cereblon (CRBN) ๋ฆฌ๊ฐ„๋“œ๋กœ, ๋ง์ปค๋ฅผ ํ†ตํ•ด ํ‘œ์  ๋‹จ๋ฐฑ์งˆ ๋ฆฌ๊ฐ„๋“œ์™€ ๊ฒฐํ•ฉํ•˜์—ฌ PROTACs(๋‹จ๋ฐฑ์งˆ ๋ถ„ํ•ด ํ‘œ์  ํ‚ค๋ฉ”๋ผ)๋ฅผ ํ˜•์„ฑํ•  ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.
S8760 Iberdomide (CC-220) Iberdomide (CC-220)์€ CRL4CRBN E3 ubiquitin ligase ๋ณตํ•ฉ์ฒด์˜ ์ผ๋ถ€์ธ cereblon์„ ํ‘œ์ ์œผ๋กœ ํ•˜๋Š” ์ƒˆ๋กœ์šด ๊ฒฝ๊ตฌ์šฉ ๋ฉด์—ญ ์กฐ์ ˆ ํ™”ํ•ฉ๋ฌผ๋กœ, ๊ฒฝ์Ÿ์  TR-FRET ๋ถ„์„์—์„œ 60 nM์˜ IC50 ๊ฐ’์„ ๋ณด์ž…๋‹ˆ๋‹ค. Iberdomide (CC-220)์€ ํ•ญ์ข…์–‘ ๋ฐ ๋ฉด์—ญ ์ž๊ทน ํ™œ์„ฑ์„ ํ†ตํ•ด apoptosis๋ฅผ ์œ ๋„ํ•ฉ๋‹ˆ๋‹ค.
S1526 Quizartinib (AC220) Quizartinib (AC220)์€ FLT3์— ๋Œ€ํ•œ 2์„ธ๋Œ€ FLT3 ์ €ํ•ด์ œ๋กœ, MV4-11 ๋ฐ RS4;11 ์„ธํฌ์—์„œ ๊ฐ๊ฐ 1.1 nM/4.2 nM์˜ IC50์„ ๋‚˜ํƒ€๋‚ด๋ฉฐ, KIT, PDGFRฮฑ, PDGFRฮฒ, RET ๋ฐ CSF-1R๋ณด๋‹ค FLT3์— ๋Œ€ํ•ด 10๋ฐฐ ๋” ์„ ํƒ์ ์ž…๋‹ˆ๋‹ค. Quizartinib (AC220)์€ ์ข…์–‘ ์„ธํฌ์˜ apoptosis๋ฅผ ์œ ๋„ํ•ฉ๋‹ˆ๋‹ค. ์ž„์ƒ 3์ƒ.
S2680 Ibrutinib (PCI-32765) Ibrutinib (PCI-32765)์€ BTK์˜ ๊ฐ•๋ ฅํ•˜๊ณ  ๋งค์šฐ ์„ ํƒ์ ์ธ ์–ต์ œ์ œ๋กœ, ๋ฌด์„ธํฌ ๋ถ„์„์—์„œ IC50์ด 0.5 nM์ด๋ฉฐ, Bmx, CSK, FGR, BRK, HCK์—๋Š” ์ ๋‹นํ•œ ํšจ๋Šฅ์„, EGFR, Yes, ErbB2, JAK3 ๋“ฑ์—๋Š” ๋” ๋‚ฎ์€ ํšจ๋Šฅ์„ ๋ณด์ž…๋‹ˆ๋‹ค. Ibrutinib์€ P13I๋ฅผ ํฌํ•จํ•œ ์ผ๋ จ์˜ PROTACs ํ•ฉ์„ฑ์— ์žˆ์–ด Target Protein Ligand์ธ BTK ๋ฆฌ๊ฐ„๋“œ๋กœ ์ ์šฉ๋  ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.
S6545 BI-4464 BI-4464๋Š” PTK2/FAK์˜ ๊ณ ๋„๋กœ ์„ ํƒ์ ์ธ ATP ๊ฒฝ์Ÿ์  ์–ต์ œ์ œ์ด๋ฉฐ, IC50 ๊ฐ’์€ 17 nM์ž…๋‹ˆ๋‹ค.
S7110 (+)-JQ1 (+)-JQ1์€ BET bromodomain ์–ต์ œ์ œ๋กœ, ์„ธํฌ ๋ฌดํ•จ์œ  ๋ถ„์„์—์„œ BRD4(1/2)์— ๋Œ€ํ•ด 77 nM/33 nM์˜ IC50์„ ๊ฐ€์ง€๋ฉฐ, BET ํŒจ๋ฐ€๋ฆฌ์˜ ๋ชจ๋“  bromodomain์— ๊ฒฐํ•ฉํ•˜์ง€๋งŒ BET ํŒจ๋ฐ€๋ฆฌ ์ด์™ธ์˜ bromodomain์—๋Š” ๊ฒฐํ•ฉํ•˜์ง€ ์•Š์Šต๋‹ˆ๋‹ค. (+)-JQ1์€ Autophagy ์œ ๋„๋ฅผ ํ†ตํ•ด ์„ธํฌ ์ฆ์‹์„ ์–ต์ œํ•ฉ๋‹ˆ๋‹ค. (+)-JQ1์€ Nuclear receptor binding SET domain protein 3 (NSD3) ํƒ€๊ฒŸ ์œ ์ „์ž์˜ ๋ฐœํ˜„์„ ์–ต์ œํ•ฉ๋‹ˆ๋‹ค.